Convatec Group Plc

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BD3VFW73
GBP
2.27
-0.05 (-2.07%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Convatec Group Plc stock-summary
stock-summary
Convatec Group Plc
Pharmaceuticals & Biotechnology
ConvaTec Group PLC is a United Kingdom-based medical product and technology company. The Company focuses on therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care, continence and critical care and infusion devices used in the treatment of diabetes and other conditions. It operates across market franchises, such as Advanced Wound Care, which provides advanced wound dressings and skin care products; Ostomy Care, which provides devices, accessories and services for people with a stoma, resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity and other causes; Continence and Critical Care, which provides products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida and other causes, and Infusion Devices, which provide disposable infusion sets.
Company Coordinates stock-summary
Company Details
Fl 7, 3 Forbury Place, 23 Forbury Road , READING None : RG1 3JH
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.31%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. John McAdam
Independent Non-Executive Chairman of the Board
Mr. Karim Bitar
Chief Executive Officer, Executive Director
Mr. Frank Schulkes
Chief Financial Officer, Executive Director
Mr. Rick Anderson
Non-Executive Director
Mr. Constantin Freng
Non-Executive Director
Ms. Heather Mason
Non-Executive Director
Mr. Sten Scheibye
Non-Executive Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 4,535 Million (Mid Cap)

stock-summary
P/E

27.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.65

stock-summary
Return on Equity

13.52%

stock-summary
Price to Book

3.43